---
schema_version: "secwatch.filing_event.v1"
accession: "0000950103-24-000379"
form_type: "8-K"
ticker: "PGEN"
cik: "0001356090"
company_name: "PRECIGEN, INC."
filed_at: "2024-01-08T23:59:59+00:00"
generated_at: "2026-06-07T02:05:57.594980+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# Precigen announces PRGN-2012 Phase 2 data expected Q2 2024; BLA submission planned H2 2024

## Summary
- PRGN-2012 Phase 2 pivotal data in RRP anticipated Q2 2024; BLA submission under accelerated approval H2 2024.
- Commercial readiness preparations underway for potential PRGN-2012 launch in 2025.
- PRGN-2009 Phase 2 study in OPSCC enrolling; cervical cancer trial to start Q1 2024.
- PRGN-3006 Phase 1b dose expansion interim data expected H2 2024; Phase 1 showed 27% ORR in r/r AML.
- New CD19 UltraCAR-T preclinical data presented; Phase 1 study preparation underway.

## SEC filing metadata
- accession: 0000950103-24-000379
- form_type: 8-K
- ticker: PGEN
- cik: 0001356090
- company_name: PRECIGEN, INC.
- filed_at: 2024-01-08T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1356090/000095010324000379/0000950103-24-000379-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1356090/000095010324000379/dp205018_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000950103-24-000379
- JSON: https://secwatch.observer/filing/0000950103-24-000379.json
- Plain text: https://secwatch.observer/filing/0000950103-24-000379.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.